Figure 4.

AAV9-aGRIK2 treatment improves comorbidities in epileptic mice

(A) Representative images of pilocarpine mice treated with either diluent (top) or AAV9-aGRIK2 (bottom). (B) Health severity score categories measured in naive non-epileptic and epileptic mice treated with either diluent or AAV9-aGRIK2; yellow is low health and dark blue normal health. (C) Health severity score of naive non-epileptic and epileptic mice with either diluent or AAV9-aGRIK2. ∗∗∗∗p < 0.0001, two-way ANOVA repeated measure followed by Sidak’s multiple comparison test. (D) Schematic representation of the light-dark box. (E) Numbers of entry into the light zone. (F) Time spent in the light zone. (G) Schematic representation of the Y-Maze. (H) Spontaneous correct alternation in the Y-Maze (%). (I) Schematic representation of the novel arm maze. (J) Time spent in the novel arm (%). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, one-way ANOVA Tukey’s multiple comparisons test in (E)–(J). Data are reported as mean ± SEM.